<DOC>
	<DOCNO>NCT02472912</DOCNO>
	<brief_summary>Double-Blind , 3-Way Parallel Study Compare Pharmacokinetics , Safety Tolerability BMO-2 EU US Sourced Humira® Administered Single Dose ( 40 mg ) Subcutaneous Injection Healthy Adults .</brief_summary>
	<brief_title>Adalimumab PK Bioequivalence Study EU US Sourced Humira</brief_title>
	<detailed_description>This single-center , randomize , double-blind , 3-way parallel study 270 healthy adult male female subject . During study , PK bioequivalence BMO-2 , contain 40 mg adalimumab , compare EU license Humira® ( EU-Humira® ) ( 40 mg ) US license Humira® ( US-Humira® ) ( 40 mg ) . Randomization stratify body weight ( weight category 60.0-79.9 kg 80.0-95.0 kg ) . After randomization , subject receive one follow treatment : single sc injection 40 mg BMO-2 , equivalent sc injection EU-Humira® ( 40 mg ) , equivalent sc injection US-Humira® ( 40 mg ) . Volunteers participation study expect finish follow-up visit , schedule 70 day injection study drug .</detailed_description>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Weight : 60.095.0 kg . Body mass index ( BMI ) : 19.030.0 kg/m2 , inclusive Medical history without major pathology . Systolic blood pressure ≤150 mmHg diastolic blood pressure ≤90 mmHg . Computerized ( 12lead ) electrocardiogram ( ECG ) record without sign clinically relevant pathology Nonsmoker light smoker Ability willingness abstain alcohol 48 h prior drug administration 48h prior ambulatory visit , stay clinical research center discharge inhouse period . Fertile male females participate heterosexual sexual relation : willingness use adequate contraception screen 90 day followup visit Females must lactate must negative pregnancy test screen admission Differentiation leukocytes , platelet count , hematocrit hemoglobin result within reference range . Minor deviation consider lack clinical relevance Principal Investigator accept . All value hematology biochemistry test blood urine within normal range show clinically relevant deviation judge Principal Investigator . Other protocoldefined inclusion/exclusion criterion may apply History relevant drug and/or food allergy . Hypersensitivity Humira® constituent . Known history previous exposure anti TNFalpha molecule . Any past concurrent medical condition potentially increase subject 's risk . Examples include medical history evidence clinically relevant pathology ( e.g. , malignancy , demyelinate disorder ) . Presence chronic obstructive pulmonary disease ( COPD ) . Asthma childhood allow Any current active infection , include localized infection , recent history Treatment nontopical medication ( include counter medication , herbal remedy St. John 's Wort extract ) within 7 day prior study drug administration , exception hormonal contraceptive , multivitamin , vitamin C , food supplement limit amount acetaminophen , may use throughout study . History active tuberculosis presence active latent tuberculosis . Having reside traveled region tuberculosis mycosis endemic within 90 day screen , intend visit region period 3 month dose . Having receive live vaccine past 4 week screen intention receive vaccination study . Participation drug study within 60 day 5 halflives previous drug ( know ) , whichever longer , prior drug administration Donation 500 mL blood within 8 week prior drug administration . History alcohol abuse drug addiction ( include soft drug like cannabis product ) . Positive urine drug screen ( opiate , methadone , cocaine , amphetamine ( include XTC metamphetamines ) , cannabinoids , barbiturate , benzodiazepine , tricyclic antidepressant ) positive alcohol breath test . Positive screen Hepatitis B surface antigen ( HBsAg ) , antiHepatitis C virus antibody ( HCV ) , antihuman immunodeficiency virus 1/2 antibody ( HIV ) . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Biosimilar Pharmaceuticals</keyword>
</DOC>